Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Post by willibrichon Nov 30, 2010 12:07pm
604 Views
Post# 17777086

Mirador should be uniform

Mirador should be uniformin porosity and thus in pressures throughout the formation.
And having worked in the oil patch for most of my career, I can read between the lines of QEI's discovery well announcement, with several more weeks of testing needed.
With such a large amount of oil from a discovery well, it results in a significant logistical problem of what to do with all that oil from an extended flow test. You need alot of storage capacity on site for all that oil. And that is the situation , even if they do not use any pumping procedures .
Hence the reason for Quetzel's decision to stop flow testing after only 5 feet of the Mirador.
  
You will note from other press releases of companies in the Llanos Basin that pumps are often  not used in a significantly large volume discovery wells. Except for when a pipeline is close by to take on the extra volumes of oil.
 Because the company knows that they have a new production well and they will wait until a pipeline is close enough before they maximize production flows. Pumps can increase production by 40 to 100 %.
 
Thank you for the extra low priced shares.

  
Bullboard Posts